|Bid||103.28 x 800|
|Ask||103.29 x 800|
|Day's Range||101.60 - 103.44|
|52 Week Range||72.06 - 106.45|
|Beta (5Y Monthly)||0.60|
|PE Ratio (TTM)||13.71|
|Forward Dividend & Yield||1.68 (1.64%)|
|Ex-Dividend Date||Aug 14, 2020|
|1y Target Est||N/A|
AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2020 third quarter ended June 30, 2020, revenue increased 0.3 percent year-over-year to $45.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.41 for the June quarter of fiscal 2020, compared to $1.43 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 5.1 percent to $1.85 in the fiscal third quarter.
AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter Fiscal 2020 on Wednesday, August 5, 2020, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2020.
AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib). AmerisourceBergen is providing a unified commercialization approach for QINLOCK which was approved by the U.S. Food and Drug Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally administered kinase switch control inhibitor approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.